EU Makes Sanofi Flu Vaccine Commitments Binding
European Commission ensures Sanofi stops disparaging rival flu vaccine Fluad in Germany and France through March 2030.
Updated on Nov. 4, 2026 in COVID-19
The European Commission has made legally binding commitments from Sanofi addressing alleged disparagement of competing flu vaccine Fluad. The commitments cover Germany and France and run until March 2030.
Why it matters
The Commission's preliminary concerns centered on alleged potentially misleading communications to healthcare professionals that may have restricted competition under Article 102 TFEU. Binding commitments aim to protect fair competition in influenza vaccine markets.
The commitments were developed after a market test in July and August 2026 and run 24 months for the published clarifying statement, through March 2030. Sanofi's exact market share for Fluad against Efluelda, and the full extent of any harm to competition, were not quantified in the extraction.
The players
European Commission
The executive body of the European Union responsible for proposing legislation and enforcing EU competition law, including Article 102 TFEU.
Sanofi
A French multinational pharmaceutical company and one of the world's largest vaccine manufacturers, which markets the influenza vaccines Fluad and Efluelda.
The details
Sanofi committed to refrain from promotional statements in Germany and France that criticize national vaccination recommendations or portray Fluad negatively. The company will publish a clarifying statement stating that national recommendations consider Fluad and Efluelda equivalent in protecting elderly people against influenza, and a monitoring trustee will report regularly to the Commission.
Timeline
Between 2024 and autumn 2025: alleged disparagement communication campaigns occurred.
July to August 2026: market test conducted on Sanofi's proposal.
November 3, 2026: Commission made the commitments legally binding.
March 2030: Sanofi's commitments expire.
Big Picture
The case applies Article 102 TFEU, the EU's prohibition on abuse of dominant market position, to promotional communications by a pharmaceutical company toward healthcare professionals. It follows the Commission's use of binding commitments rather than a formal infringement decision to resolve competition concerns.
Patients and clinicians in Germany and France should see clarifying statements that describe Fluad and Efluelda as equivalent in protecting elderly people against influenza. Promotional materials are expected to reference national vaccination recommendations rather than criticize them.
The takeaway
Clinicians choosing between influenza vaccines for elderly patients can rely on national vaccination recommendations, which the clarifying statement says treat Fluad and Efluelda as equivalent in protection.
Further reading
Explore more COVID-19 coverage for broader context on the influenza vaccine market.
